Researchers have reported that the drug, erenumab, can significantly reduce previously untreatable migraine attacks. The drug has been tested in patients with challenging migraine that is resilient to treatment and erenumab has been reported to reduce episodes of migraine by 50 percent in one-third of the participants. The study was conducted by researchers at The Charité - University Medicine, Berlin in Germany and the results will soon be presented at the American Academy of Neurology's 70th Annual Meeting that is to be held in Los Angeles, USA.
Migraine is a neurological disorder that has no definite cure till date. This study was conducted on 246 patients with an untreatable migraine. Thirty-nine percent of the participants had tried two different medications without success, Thirty-eight percent had tried three, while twenty-three percent had tried at least four different…
